Leerink Partnrs Issues Pessimistic Outlook for FULC Earnings

Key Points

• Leerink Partners has revised its Q3 2025 EPS estimate for Fulcrum Therapeutics to ($0.34) per share, down from a prior forecast of ($0.30).
• Multiple analysts have upgraded Fulcrum Therapeutics, with price target increases indicating a consensus target price of $7.57, reflecting a strong interest in the stock.
• The company is focused on developing treatments for genetically defined diseases, with key products in clinical trials aimed at addressing high unmet medical needs.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings estimates for Fulcrum Therapeutics in a report released on Tuesday, July 29th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.34) for the quarter, down from their previous forecast of ($0.30). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics' Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.24) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.33) EPS and FY2027 earnings at ($1.17) EPS.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01.

Other equities analysts have also recently issued reports about the company. Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price objective (up from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. HC Wainwright upgraded Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the company from $4.00 to $12.00 in a research report on Tuesday, July 29th. Cantor Fitzgerald upgraded Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective on the stock in a report on Thursday, May 15th. Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. Finally, Royal Bank Of Canada increased their price target on Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a "sector perform" rating in a report on Wednesday, July 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $7.57.

Fulcrum Therapeutics Trading Down 1.7%

Shares of FULC traded down $0.12 during mid-day trading on Friday, reaching $6.85. The company's stock had a trading volume of 287,607 shares, compared to its average volume of 591,881. Fulcrum Therapeutics has a 1-year low of $2.32 and a 1-year high of $10.13. The stock has a market cap of $370.25 million, a P/E ratio of -5.63 and a beta of 2.47. The business has a 50-day simple moving average of $7.18 and a two-hundred day simple moving average of $5.02.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC lifted its stake in Fulcrum Therapeutics by 182.3% in the fourth quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock valued at $15,691,000 after buying an additional 2,155,675 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Fulcrum Therapeutics by 50.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company's stock valued at $14,100,000 after purchasing an additional 1,000,000 shares in the last quarter. Woodline Partners LP raised its holdings in Fulcrum Therapeutics by 110.3% in the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock valued at $6,629,000 after buying an additional 739,713 shares during the last quarter. Exome Asset Management LLC raised its holdings in Fulcrum Therapeutics by 143.0% during the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company's stock worth $1,985,000 after purchasing an additional 405,538 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in Fulcrum Therapeutics by 865.0% in the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company's stock valued at $989,000 after purchasing an additional 308,854 shares during the period. Institutional investors and hedge funds own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.